Qian Jiang1,2, Lu Yu3, Robert Peter Gale4. 1. Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Beijing, China. jiangqian@medmail.com.cn. 2. Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. jiangqian@medmail.com.cn. 3. Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Beijing, China. 4. Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.
Abstract
PURPOSE: To explore patients' and hematologists' concerns regarding tyrosine kinaseinhibitor (TKI)-therapy and identify variables associated these concerns. Methods A cross-sectional questionnaire including 16 common issues related to TKI-therapy was distributed to adults with chronic myeloid leukemia (CML) receiving TKIs and hematologists treating CML patients and answered anonymously. RESULTS: Data from 1518 patient respondents receiving TKI-therapy ≥ 3 months were analyzed. 939 (62%) were male. Median age was 42 years. 72% were receiving imatinib. Median TKI-therapy duration was 27 months. Data from 259 hematologist respondents were analyzable. 154 (59%) treated > 5 persons with CML per month. Median number of concerns was 5 (range 0-16) for both patients and hematologists. The top five issues for both cohorts were new drug development, stopping TKI-therapy, TKI-reimbursement policies, TKI-related adverse effects and long-term efficacy of TKIs. 12 issues attracted proportionally discordant attention between patients and hematologists. Patients were more concerned with TKI-reimbursement policies, price reduction of TKIs, TKI-related adverse effects, restrictions to daily life, CML knowledge and interpretation of laboratory data, whereas hematologists were more concerned with stopping TKI-therapy, TKI choice, monitoring, TKI dose-adjustment, quality of generics and switching between branded and generic TKIs. In multivariate analyses female sex [OR = 1.4 (1.1-1.7); p = 0.008], education level ≥ bachelor e[OR = 1.8 (1.4-2.2); p < 0.001], TKI-therapy duration 36-< 60 months [OR = 1.4 (1.0-1.9); p = 0.049] and having adverse impact on daily life and work [OR = 1.5 (1.2-1.8]; p = 0.001] were associated with greater numbers of patients' concerns. CONCLUSIONS: Our data suggested hematologists need to be aware of CML patients' concerns to improve their quality-of-life and patient-hematologist communication.
PURPOSE: To explore patients' and hematologists' concerns regarding tyrosine kinaseinhibitor (TKI)-therapy and identify variables associated these concerns. Methods A cross-sectional questionnaire including 16 common issues related to TKI-therapy was distributed to adults with chronic myeloid leukemia (CML) receiving TKIs and hematologists treating CMLpatients and answered anonymously. RESULTS: Data from 1518 patient respondents receiving TKI-therapy ≥ 3 months were analyzed. 939 (62%) were male. Median age was 42 years. 72% were receiving imatinib. Median TKI-therapy duration was 27 months. Data from 259 hematologist respondents were analyzable. 154 (59%) treated > 5 persons with CML per month. Median number of concerns was 5 (range 0-16) for both patients and hematologists. The top five issues for both cohorts were new drug development, stopping TKI-therapy, TKI-reimbursement policies, TKI-related adverse effects and long-term efficacy of TKIs. 12 issues attracted proportionally discordant attention between patients and hematologists. Patients were more concerned with TKI-reimbursement policies, price reduction of TKIs, TKI-related adverse effects, restrictions to daily life, CML knowledge and interpretation of laboratory data, whereas hematologists were more concerned with stopping TKI-therapy, TKI choice, monitoring, TKI dose-adjustment, quality of generics and switching between branded and generic TKIs. In multivariate analyses female sex [OR = 1.4 (1.1-1.7); p = 0.008], education level ≥ bachelor e[OR = 1.8 (1.4-2.2); p < 0.001], TKI-therapy duration 36-< 60 months [OR = 1.4 (1.0-1.9); p = 0.049] and having adverse impact on daily life and work [OR = 1.5 (1.2-1.8]; p = 0.001] were associated with greater numbers of patients' concerns. CONCLUSIONS: Our data suggested hematologists need to be aware of CMLpatients' concerns to improve their quality-of-life and patient-hematologist communication.
Authors: Amr R Ibrahim; Lina Eliasson; Jane F Apperley; Dragana Milojkovic; Marco Bua; Richard Szydlo; Francois-Xavier Mahon; Kasia Kozlowski; Christos Paliompeis; Letizia Foroni; Jamshid S Khorashad; Alex Bazeos; Mathieu Molimard; Alistair Reid; Katayoun Rezvani; Gareth Gerrard; John Goldman; David Marin Journal: Blood Date: 2011-02-23 Impact factor: 22.113
Authors: David P Steensma; Rami S Komrokji; Richard M Stone; Alan F List; Guillermo Garcia-Manero; John M Huber; Betsy Dennison; Mikkael A Sekeres Journal: Cancer Date: 2014-02-27 Impact factor: 6.860
Authors: Lei Chen; Annie Guérin; Jipan Xie; Eric Q Wu; Andrew P Yu; Solveig G Ericson; Elias Jabbour Journal: Curr Med Res Opin Date: 2012-11-05 Impact factor: 2.580
Authors: Stuart L Goldberg; Jorge E Cortes; Carlo Gambacorti-Passerini; Rüdiger Hehlmann; H Jean Khoury; Mauricette Michallet; Ron L Paquette; Bengt Simonsson; Teresa Zyczynski; Aimee Foreman; Elisabetta Abruzzese; David Andorsky; Aart Beeker; Pascale Cony-Makhoul; Richard Hansen; Elza Lomaia; Eduardo Olavarria; Michael J Mauro Journal: Am J Hematol Date: 2017-09-25 Impact factor: 10.047
Authors: Ruben A Mesa; Carole B Miller; Maureen Thyne; James Mangan; Sara Goldberger; Salman Fazal; Xiaomei Ma; Wendy Wilson; Dilan C Paranagama; David G Dubinski; Ahmad Naim; Shreekant Parasuraman; John Boyle; John O Mascarenhas Journal: Cancer Date: 2016-09-30 Impact factor: 6.860